On the association between circulating biomarkers and atherosclerotic calcification in a cohort of arterial disease participants by Cahalane, Rachel M. et al.
Nutrition, Metabolism & Cardiovascular Diseases (2021) 31, 1533e1541Available online at www.sciencedirect.com
Nutrition, Metabolism & Cardiovascular Diseases
journal homepage: www.e lsev ie r .com/ locate/nmcdOn the association between circulating biomarkers and
atherosclerotic calcification in a cohort of arterial disease
participants
Rachel M. Cahalane a, Hilary E. Barrett a, Aisling M. Ross a, John J.E. Mulvihill a,b,
Helen Purtill b,c, Logeswaran Selvarajah d, Julie O'Brien d, Eamon G. Kavanagh e,
Michael A. Moloneye e, Siobhan M. Egan f, Fiona C. Leahy f, Tomás P. Griffin g,h,
M.N. Islam h,i, Paul M. O'Shea i, Michael T. Walsh a,b, Eibhlís M. O'Connor b,j,k,*
a BioScience and BioEngineering Research, Biomaterials Cluster, Bernal Institute, School of Engineering, University of Limerick, Ireland
bHealth Research Institute, University of Limerick, Ireland
c Department of Mathematics and Statistics, Aging Research Centre, University of Limerick, Ireland
dDepartment of Radiology, University Hospital Limerick, Ireland
eDepartment of Vascular Surgery, University Hospital Limerick, Ireland
f Clinical Research Support Unit, University Hospital Limerick, Ireland
g Centre for Endocrinology, Diabetes and Metabolism, Saolta University Health Care Group (SUHCG), Galway University Hospitals, Galway, Ireland
h Regenerative Medicine Institute (REMEDI) at CÚRAM SFI Research Centre, School of Medicine, National University of Ireland Galway, Galway, Ireland
i Department of Clinical Biochemistry, University Hospital Galway, Ireland
j Department of Biological Sciences, School of Natural Sciences, University of Limerick, Ireland
k Alimentary Pharmabiotic Centre, Microbiome Institute, University College Cork, IrelandReceived 10 July 2020; received in revised form 18 January 2021; accepted 3 February 2021
Handling Editor: F.P. Cappuccio








diseaseAbbreviations: CAC, Coronary Artery C
CVF, Calcified Volume Fraction; dp-u
tional Council for Harmonisation of Te
Protein; Micro-CT, Micro-Computed T
* Corresponding author. Department o
E-mail addresses: rachelcahalane93@
mulvihill@ul.ie (J.J.E. Mulvihill), helen.pu
kavanagh@icloud.com (E.G. Kavanagh),
C. Leahy), Tomas.Griffin1@hse.ie (T.P. Gr
(M.T. Walsh), eibhlis.oconnor@ul.ie (E.M
https://doi.org/10.1016/j.numecd.2021.02.005
0939-4753/ª 2021 The Italian Diabetes Society
Medicine and Surgery, Federico II University. PuAbstract Background and aims: Atherosclerotic calcification is a powerful predictor of cardio-
vascular disease. This study aims to determine whether circulating levels of a local/systemic
calcification inhibitor or a marker of bone formation correlate with measures of coronary or ex-
tracoronary calcification.
Methods and results: Clinical computed tomography (CT) was performed on 64 arterial disease
participants undergoing carotid and lower extremity endarterectomy. Coronary artery calcium
(CAC) scores and volumes were acquired from the CT scans (n Z 42). CAC scores and volumes
were used to derive CAC density scores. Micro-CT was performed on excised carotid (n Z 36)
and lower extremity (n Z 31) plaques to quantify the volume and volume fraction of extracor-
onary calcification. Circulating levels of dephospho-uncarboxylated Matrix Gla Protein (dp-
ucMGP), fetuin-A, carboxylated and uncarboxylated osteocalcin (ucOC) were quantified using
commercial immunoassays. Carotid participant CAC density scores were moderately negatively
correlated with plasma dp-ucMGP (rs Z 0.592, P Z 0.008). A weak negative association was
found between CAC scores and %ucOC for all participants (rs Z 0.335, PZ 0.040). Another weak
negative correlation was observed between fetuin-A and the volume of calcification withinalcium; cOC, Carboxylated Osteocalcin; CT, Computed Tomography; CVD, Cardiovascular Disease;
cMGP, dephospho-uncarboxylated Matrix Gla Protein; HU, Hounsfield Unit; ICH-GCP, The Interna-
chnical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice; MGP, Matrix Gla
omography; ucOC, uncarboxylated Osteocalcin; VKDP, Vitamin K-Dependent Proteins.
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1534 R.M. Cahalane et al.excised carotid specimens (rs Z 0.366, P Z 0.031). Despite substantial differences in coronary
and extracoronary calcium measurements, the levels of circulating biomarkers did not vary
significantly between carotid and lower extremity subgroups.
Conclusion: Correlations identified between circulating biomarkers and measures of coronary
and extracoronary calcium were not consistent among participant subgroups. Further research
is required to determine the association between circulating biomarkers, coronary and extracor-
onary calcium.
ª 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian
Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II
University. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Individuals with subclinical atherosclerosis are a priority
for risk stratification and primary prevention of major
adverse cardiovascular events including myocardial and
cerebral infarctions [1]. The Coronary Artery Calcium (CAC)
Score [2] is a widely used marker of atherosclerotic burden
[3] and is a powerful predictor of cardiovascular morbidity
and mortality [4]. It is well-documented that atheroscle-
rosis is a systemic disease [5] and large volumes of calci-
fication in distinct vascular territories are associated with
increased cardiovascular disease (CVD) mortality [6].
Therefore, screening for calcification in the coronary ar-
teries alone may have limited value in estimating the
atherosclerotic burden [7]. However, utilising whole-body
CT to quantify the calcific burden in all major atheroscle-
rotic vessels is not without its challenges, including
increased cost and radiation dose [8].
Blood-based biomarkers may provide an alternative
diagnostic approach. The active formation of atheroscle-
rotic calcification [9] provides a unique opportunity to
examine the utility of circulating biomarkers of vascular
calcification to characterise atherosclerotic plaques based
on the calcified content. Arterial tissues are in immediate
contact with circulating blood, making this a feasible
approach for the subclassification of CVD [10].
Matrix g-carboxyglutamate (Gla) protein (MGP) is a
potent inhibitor of vascular calcification expressed locally
by vascular smooth muscle cells [11]. The dephosphory-
lated and uncarboxylated isoform of this protein (dp-
ucMGP) has a low affinity for intravascular calcium de-
posits and is readily released into circulation [12]. This
inactive MGP species has been proposed as a biomarker of
cardiovascular risk [13] and vascular calcification
[12,14,15]. Fetuin-A is a circulating plasma glycoprotein
produced by the liver, which contributes to the systemic
calcification inhibitory capacity of the circulating blood
[16]. Osteocalcin is a marker of bone turnover and osteo-
blast activity [17].
The main objective of this study was to determine the
association between circulating levels of a local or sys-
temic calcification inhibitor (dp-ucMGP and fetuin-A), a
marker of bone formation (osteocalcin) and either coro-
nary and extracoronary calcium measurements. A sub-
objective of this study was to compare the calcium mea-
surements and the levels of circulating biomarkersbetween participants undergoing carotid versus lower
extremity endarterectomy procedures.Methods
Recruitment
Arterial disease participants undergoing standard carotid
and lower extremity endarterectomy at the University
Hospital Limerick, Ireland were recruited for this study
(n Z 64). Written informed consent was acquired from all
participants. This study was approved by the Research
Ethics Committee at the University Hospital Limerick and
conforms to the principles of ICH-GCP and the Declaration
of Helsinki. Preoperative participant assessment included
demographics, comorbid conditions, preoperative medi-
cation and cardiovascular history, as presented in Table 1.
Sample acquisition
Blood samples
Fasting venous blood was preoperatively collected by
venepuncture (n Z 64). Serum samples were prepared in
serum gel tubes (S-Monovette 4.9 mL Z-Gel, Sarstedt, UK)
and plasma samples were prepared in K3EDTA plasma
tubes (S-Monovette 7.5 mL K3E, Sarstedt, UK) both by
standard centrifugation (15 min, 1580g). Serum and
plasma samples were split into dedicated aliquots and
stored at 80 C until time of protein quantification.
Atherosclerotic plaques
Plaquespecimenswereacquiredfrom64differentparticipants
undergoing carotid and lower extremity endarterectomy: 67
plaquespecimens in total, 36carotidand31 lowerextremity (2
aorto-iliac and 29 ilio-femoral). Therewere 3 participants that
underwent two separate endarterectomy procedures (multi-
ple [n Z 3]). Within 24 h of surgical removal, the plaque
samples were frozen in phosphate-buffered saline solution
and stored at20 C until time of analysis.
Coronary artery calcium imaging
Coronary CT scanning was performed for 55 of the par-
ticipants; 2 preoperatively and 53 postoperatively (post-
operative duration 51  54 days, maximum 32 weeks),










Age, years (mean  SDb) 68  9 70  9 66  10 0.165 68  11
Sex, Male, n (%) 45 (70) 22 (63) 20 (77) 0.570 3 (100)
Comorbidities
Systolic Blood Pressure (mmHg) (mean  SD) 147  24 152  24 139  23 0.043 150  31
Diastolic Blood Pressure (mmHg) (mean  SD) 76  15 80  16 71  11 0.011 67  17
Body Mass Index (kg/m2) (mean  SD) 26  5 27  5 26  5 0.370 25  4
Obesity, n (%) 11 (17) 7 (20) 4 (15) 0.883 0 (0)
Smoker (current or ex), n (%) 56 (88) 29 (83) 24 (92) 0.280 3 (100)
Diabetes Mellitus, n (%) 19 (30) 6 (17) 12 (46) 0.014 1 (33)
Dyslipidemia, n (%) 52 (81) 27 (77) 23 (88) 0.285 2 (67)
Hypertension, n (%) 51 (80) 28 (80) 20 (77) 0.772 3 (100)
Atrial Fibrillation, n (%) 11 (17) 5 (14) 5 (19) 0.606 1 (33)
Chronic Obstructive Pulmonary Disease, n (%) 10 (16) 3 (9) 5 (19) 0.223 2 (67)
Osteoporosis, n (%) 4 (6) 2 (6) 2 (8) 0.758 0 (0)
Increased C2H5OH Levels, n (%) 5 (8) 3 (9) 2 (8) 0.901 0 (0)
Medication
Ace Inhibitor, n (%) 19 (30) 8 (23) 9 (35) 0.311 2 (67)
Angiotensin 2 Receptor Blocker, n (%) 15 (23) 9 (26) 6 (23) 0.813 0 (0)
B Blocker, n (%) 29 (45) 15 (43) 12 (46) 0.798 2 (67)
Calcium Antagonist, n (%) 23 (36) 13 (37) 9 (35) 0.839 1 (33)
Nitrates, n (%) 2 (3) 1 (3) 1 (4) 0.968 0 (0)
Anticoagulant Therapy, n (%) 11 (17) 5 (14) 6 (23) 0.115 0 (0)
Antiplatelet, n (%) 20 (31) 8 (23) 11 (42) 0.105 1 (33)
Aspirin, n (%) 51 (80) 28 (80) 20 (77) 0.772 3 (100)
Insulin, n (%) 6 (9) 1 (3) 4 (15) 0.078 1 (33)
Oral Hypoglycaemic, n (%) 15 (23) 5 (14) 9 (35) 0.062 1 (33)
Statin, n (%) 54 (84) 29 (83) 22 (85) 0.854 3 (100)
Cardiovascular History
Ischemic Heart Disease, n (%) 30 (47) 16 (46) 13 (50) 0.740 1 (33)
Previous Cardiac Event, n (%) 10 (16) 5 (14) 5 (19) 0.606 0 (0)
Lower Limb Peripheral Artery Disease, n (%) 36 (56) 7 (20) 26 (100) <0.001 3 (100)
Previous Cerebrovascular Event, n (%) 36 (56) 32 (91) 2 (8) <0.001 2 (67)
a P-value compares carotid and lower extremity groups.
b SD Z Standard Deviation.
Arterial calcification and circulating biomarkers 1535using a Siemens Somatom Sensation 64 (Erlangen, Ger-
many). The scanning parameters were 200 mm field of
view, 3 mm slice thickness, acquisition 24  1.2 mm and
reconstruction increment of 1.5 mm. The x-ray source was
operated at 120 kV and all tomographic slices were ob-
tained with a rotation time of 0.33 s and pitch of 0.2. CAC
scores and volumes were acquired using Syngo calcium
scoring software (Siemens AG, Erlangen, Germany). CAC
scan results for participants with coronary artery bypass
grafts (CABG) (nZ 8), pacemakers (nZ 2), coronary stents
(n Z 2) or a CABG and a pacemaker (n Z 1) were
excluded. Based on the methodology of Criqui et al., the
average CAC density scores were calculated by dividing the
CAC scores by the average area scores for each participant,
where the average score is estimated as the CAC volume
divided by the CT slice thickness [18]. Participants with a
CAC score of zero could not be included in CAC density
score analysis (n Z 3).
Plaque-specific image acquisition and post processing
As the standard preoperative image assessment of pe-
ripheral arterial disease varied on a case-by-case basis, thecalcified content within the excised plaque samples was
determined using ex vivo high-resolution micro-CT imag-
ing postoperatively.
Chemical fixation
To prevent any destructive effects to the tissue structure
under the intense micro-CT voltage source, the specimens
underwent a previously described preservation process
involving chemical fixation with methanol, dehydration
with ethanol and drying with hexamethyldisilazane [19].
Scanning parameters
The scanning was performed with a 0.4x optical magni-
fication, low energy pass filter and 2.5 s x-ray exposure
time. The x-ray source was operated at 50 kV and 81 mA
and all tomographic slices were obtained with a pixel
resolution of 15.68 mm (Xradia versa 500, Zeiss, Ger-
many). Images were calibrated to Hounsfield Unit values
(HU).
Calcification quantification
The calcified portions of the excised plaques were quan-
tified based on the standard radiographic density
1536 R.M. Cahalane et al.thresholds (130HU) using ImageJ (National Institutes of
Health, Maryland, USA). The volume of calcification is
calculated by multiplying the number of calcified pixels by
the known voxel volume. The degree of excised plaque
calcification is represented by the calcified volume fraction
(CVF), the ratio of calcification volume to total plaque
volume [20].
Protein quantification
Circulating plasma levels of dp-ucMGP levels were
quantified using the inaKtif MGP iSYS kit analysed on the
IDS-iSYS Multi-Discipline Automated System (Immuno-
DiagnosticSystems, Boldon, UK). Sample aliquots under-
went a minimum of 1 and a maximum of 3 freezeethaw
cycles before dp-ucMGP quantification. Circulating
plasma levels of fetuin-A and serum levels of cOC andFigure 1 Flow chart of participant sample acquisition, measurements perfo
Blood samples were acquired from the participants preoperatively (n Z 64).
ucMGP), fetuin-A and carboxylated or uncarboxylated osteocalcin (cOC and
were excluded from the vitamin K-dependent protein analysis (dp-ucMGP
cedures (n Z 67). Calcification volume and calcified volume fraction withi
scans were performed (n Z 55). Participants with the presence of coronary
the CAC analysis (n Z 13). CAC scores, CAC volumes and average CAC densucOC were quantified using commercially available ELISA
test kits (Bio-techne, R&D Systems (MN, USA) Cat. No.
DFTA00, and TaKaRa Bio Inc (Japan) Cat. No. MK111 and
MK118, respectively). Samples were analysed in duplicate
and ELISAs were carried out in accordance with the
manufacturer's instructions. Results were read on a
multi-mode plate reader (Synergy H1, BioTek, VT, USA).
Samples underwent 1 freezeethaw cycle prior to protein
quantification. Circulating osteocalcin is described using
percentage uncarboxylated osteocalcin to total osteo-
calcin (%ucOC). Both MGP and osteocalcin are vitamin K-
dependent proteins (VKDP) that require carboxylation to
become fully functional [21,22]. Any participants who
were receiving warfarin (vitamin K antagonist) at the
time of or prior to recruitment were excluded from the
VKDP analysis (dp-ucMGP and %ucOC) (n Z 5). Fig. 1
presents an overview of the sample acquisition,rmed and any exclusion criteria. Sixty-four participants were recruited.
Circulating levels of dephospho-uncarboxylated Matrix Gla Protein (dp-
ucOC) were measured. Any participants that were prescribed warfarin
and %ucOC) (n Z 5). Plaques were acquired from endarterectomy pro-
n the excised plaques was determined. Coronary artery calcium (CAC)
artery bypass grafts (CABG), pacemakers or stents were excluded from
ity scores were calculated from the scans.
Figure 2 Scatterplots of circulating biomarkers versus measures of coronary calcification. Dephospho-uncarboxylated Matrix Gla Protein (dp-
ucMGP) versus (A) coronary artery calcium (CAC) score (B) CAC volume and (C) CAC density. Fetuin-A versus (D) CAC score (E) CAC volume and (F)
CAC density. Percentage uncarboxylated osteocalcin (%ucOC) versus (G) CAC score (H) CAC volume and (I) CAC density.
Arterial calcification and circulating biomarkers 1537recorded measurements and any exclusion criteria that
were utilised in this study.
Statistical analysis
Statistical analysis was performed using IBM SPSS Sta-
tistics version 26. Descriptive statistics were used to
summarise participant characteristics. Participants are
grouped according to endarterectomy location (carotid,
lower extremity and multiple). Categorical data were
compared across groups using Chi-squared tests.
ShapiroeWilk analysis was performed to assess the
distribution of continuous data. Associations in levels of
circulating proteins (dp-ucMGP, fetuin-A and %ucOC)
and measures of atherosclerotic calcification (CAC
score, CAC volume, CAC density, calcification volume
and CVF) were examined using Spearman's rank-order
correlation coefficient (rs). Comparisons in the calcium
measurements and levels of circulating proteins be-
tween carotid and lower extremity participants are
presented in the supplementary file. All data deter-
mined to be normally distributed were summarised as
mean  SD, presented in boxplots and compared be-
tween the carotid and lower extremity groups using
independent t-tests. Similarly, all data determined to be
not normally distributed were summarised as median
values with 25th to 75th percentiles in square brackets,
presented in boxplots and compared between groupsusing ManneWhitney U tests. A two-tailed P-value less




The descriptive characteristics for participants, according
to endarterectomy location, are presented in Table 1.
Three participants underwent both carotid and lower
extremity endarterectomies and were recorded as
“multiple” location. Participants were an average of
70  9 years (63% male), 66  10 years (77% male) and
68  11 years (100% male), respectively. Carotid partici-
pants had higher systolic (152  24) and diastolic
(80  16) blood pressure than lower extremity partici-
pants (139  23, 71  11), P Z 0.043 and P Z 0.011.
Additionally, 46% of lower extremity participants were
diabetic, versus 17% of carotid (P Z 0.012). Unsurpris-
ingly, 91% of carotid participants had a preoperative ce-
rebrovascular event while only 20% exhibited lower limb
peripheral arterial disease, versus 8% and 100% of the
lower extremity participants, respectively (P < 0.001 in
both cases). Twelve samples had dp-ucMGP concentra-
tions below the detection limit (<300 pM). These sam-
ples were therefore assigned a dp-ucMGP value of 299







































































































































































































































































































































































































































































































































































































































































































































































1538 R.M. Cahalane et al.Circulating biomarkers and coronary calcium
Figure. 2 presents scatterplots of circulating dp-ucMGP,
fetuin-A and %ucOC correlated with coronary artery cal-
cium (CAC) scores, CAC volumes and average CAC density
scores. A moderate negative association was observed
between dp-ucMGP and CAC density score for the carotid
participants (rs Z 0.592, P Z 0.008). Similarly, a weak
negative correlation was also found between dp-ucMGP
and CAC density score for all participants (rs Z 0.338,
P Z 0.047). Another weak negative correlation was
observed between %ucOC and CAC scores for the total
cohort (rs Z 0.335, P Z 0.040). No significant associa-
tions were found between circulating fetuin-A and coro-
nary calcium measures. Spearman's correlation
coefficients and P-values are presented in Table 2.
Circulating biomarkers and extracoronary calcium
Figure. 3 presents scatterplots of circulating dp-ucMGP,
fetuin-A and %ucOC correlated with extracoronary cal-
cium volume and the calcified volume fraction (CVF) of
excised plaques. A weak negative correlation was found
between circulating fetuin-A levels and the volume of
calcification within excised carotid specimens
(rs Z 0.366, P Z 0.031). No other significant correlations
were found between circulating dp-ucMGP or %ucOC and
extracoronary calcium measures. Spearman's correlation
coefficients and P-values are presented in Table 2.
Comparison between carotid and lower extremity
participant calcium and biomarkers
Comparisons between carotid and lower extremity groups
are presented in full in the supplementary file. Briefly,
lower extremity endarterectomy participants had signifi-
cantly higher CAC scores and CAC volumes than carotid
participants (Figs. S1A and B). However, the CAC average
density scores were not statistically different between the
two groups (Fig. S1C). Additionally, excised lower ex-
tremity specimens had much higher volumes and volume
fractions of calcium than carotid plaques (Fig. S2). Despite
these differences in the amounts of coronary and extrac-
oronary calcium for carotid and lower extremity partici-
pants, the levels of circulating dp-ucMGP, fetuin-A and %
ucOC were not statistically different between the cohorts
(Fig. S3).
Discussion
Atherosclerotic calcification is a robust marker of cardio-
vascular disease risk. The purpose of this study was to
correlate circulating biomarkers of vascular calcification
with measures of atherosclerotic calcification derived from
in vivo coronary artery calcium scans and ex vivo micro-CT
scans of endarterectomy specimens in participants un-
dergoing carotid and lower extremity endarterectomy. A
moderate negative correlation was observed between dp-
ucMGP and CAC density scores for carotid participants.
Figure 3 Scatterplots of circulating biomarkers versus measures of extracoronary calcification. Dephospho-uncarboxylated Matrix Gla Protein (dp-
ucMGP) versus (A) calcium volume and (B) calcified volume fraction. Fetuin-A versus (C) calcium volume and (D) calcified volume fraction. Per-
centage uncarboxylated osteocalcin (%ucOC) versus (E) calcium volume and (F) calcified volume fraction.
Arterial calcification and circulating biomarkers 1539Weak negative associations were found between %ucOC
and CAC scores and between fetuin-A with and carotid
plaque calcification volume.
There is conflicting evidence on the use of dp-ucMGP as
a biomarker of cardiovascular disease morbidity and
mortality for the general population [24] and those of high
atherogenic status [25]. This study is the first to correlate
circulating non-functional MGP with CAC density mea-
surements. CAC density is inversely and significantly
associated with coronary heart disease and CVD risk [18],
while circulating dp-ucMGP has been positively associated
with coronary artery calcification in healthy women [15]
and cardiovascular mortality in participants with chronic
stable vascular disease [13]. Therefore, a negative correla-
tion would be expected between CAC density scores and
circulating dp-ucMGP. However, a significant association
was only observed for the carotid participants.
A weak negative association was found between %ucOC
with CAC scores for the total cohort. Similarly, serum ucOC
levels have been inversely related to abdominal aortic
calcification scores in male diabetic participants [26]. In
contrast, higher measures of uncarboxylated osteocalcin
and osteocalcin ratio (ucOC:OC) have been associated with
CAC scores > 0, for male subjects only [27]. However, the
association between %ucOC and CAC scores is not signifi-
cant for the carotid and lower extremity subgroups, only
for the total cohort. Recent reviews also highlighted that
there is no definitive association between osteocalcin and
vascular calcification [28] and there is limited data avail-
able on undercarboxylated OC [29].
Danziger et al. previously did not find a relationship
between circulating VKDPs (including MGP and osteo-
calcin) and vascular calcification [30]. Another review also
highlighted the lack of associations evident between
VKDPs and cardiovascular morbidity and mortality [31].Here, we also found no associations between circulating
fetuin-A and any coronary calcium measures. There is
previous conflicting evidence regarding the relationship
between serum fetuin-A and CAC scores in haemodialysis
and chronic kidney disease populations [32,33].
It has been postulated that multisite imaging may be
able to predict multiple CVD outcomes [8]. We did find a
weak negative correlation between circulating fetuin-A
and the absolute volume of carotid plaque calcification.
No other associations were determined for dp-ucMGP or %
ucOC with extracoronary calcium measures. The authors
did not encounter any previous studies which examined a
relationship between either dp-ucMGP, fetuin-A or ucOC
and extracoronary calcification. The assessment of CVD
risk using measures of extracoronary calcification requires
further research and standardisation.
The dp-ucMGP and fetuin-A levels reported in this
study are not different from values reported for healthy
reference populations; dp-ucMGP: 525  243 pM (age
66e80 years) [12] or <300e532 pM [23], and fetuin-A:
400e800 mg/mL [34]. These findings extend the observa-
tions of previous studies which did not demonstrate as-
sociations between dp-ucMGP and chronic heart disease,
stroke risk [24] or calcification [30,35,36]. Conversely,
other studies have demonstrated the potential utility of
circulating dp-ucMGP levels to indicate arterial stiffness or
calcification in specific cohorts including end-stage renal
disease, aortic valve disease [12,37] and heart failure [38].
No participants included in this study were diagnosed
with either chronic kidney disease, end-stage renal dis-
ease, or aortic valve disease.
Carotid and lower extremity participants have signifi-
cantly different coronary and extracoronary calcium
measures. The differences in excised plaque calcium con-
tent have been previously described [39,40]. Of interest,
1540 R.M. Cahalane et al.this study does not confirm that circulating calcification
inhibitors can distinguish between carotid and lower ex-
tremity populations. The implications of these findings
(supplementary file) have yet to be revealed. It is apparent
that the association between circulating levels of calcifi-
cation inhibitors and atherosclerotic calcification remains
incompletely characterised [41].
Limitations
This study has some associated limitations that merit
consideration. Firstly, quantification of calcification within
endarterectomy specimens precludes that of calcium at
other subclinical sites, such as medial calcification [42].
However, a strength of this study includes the measure-
ment of CAC density, which has not been previously
correlated with circulating MGP, fetuin-A or osteocalcin.
Secondly, this is a single time point study therefore the
prognostic value of the targeted biomarkers could not be
determined. It is also necessary to consider that circulating
levels of blood protein do not necessarily emulate tissue
levels [36,43]. Given this, and the lack of consistent sta-
tistical associations determined in this study, future work
would be beneficial which examines protein expression
within the diseased tissue.Conclusions
Improved quantification of atherosclerotic calcification
will optimise cardiovascular disease risk assessment. A
moderate negative correlation was observed between CAC
density scores and plasma dp-ucMGP (rs Z 0.592,
P Z 0.008) for carotid participants. Additionally, a weak
negative correlation was observed between circulating %
ucOC and CAC scores for the total cohort (rs Z 0.335, P Z
0.040). Carotid plaque calcification volume is negatively
associated with circulating levels of fetuin-A (rs Z 0.366,
P Z 0.031). However, these associations were not consis-
tent among all participant cohorts. The relationship be-
tween circulating blood-biomarkers and the calcified
atherosclerotic burden remains incompletely charac-
terised. Of note, while carotid and lower extremity end-
arterectomy groups had considerably different amounts of
coronary and extracoronary calcium, the levels of circu-
lating proteins were not significantly different between
the groups. Future studies should conduct whole-body
examination to quantify calcium in all arterial beds to
truly explore if there is a link between atherosclerotic
calcification and circulating biomarkers. Moreover, the
correlation between protein expressions within calcified
arterial tissue versus the levels of clinically targetable
species in the circulating blood requires examination.Author contributions
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